|
|
|
17.04.25 - 18:03
|
Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates (Business Wire)
|
|
|
Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over 9 months
Strong international business: sales up +11.1% at constant exchange rates over 9 months
VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for the third quarter of the 2024-25 financial year.
Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first 9 months of the 2024-25 financial year, Amplitude Surgical continued its growth trajectory, posting sales growth of +6.4% at constant exchange rates compared with the same period last year. Business grew both in France, with an increase of +4.7%, and internationally, with growth of +11.1% at constant exchange rates."
Consolidated sales 9 months of F...
|
|
|
17.04.25 - 08:51
|
Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares (Business Wire)
|
|
|
VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited on the Amplitude Surgical SA shares, Amplitude Surgical has been informed of the execution of undertakings from 7 shareholders to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company's capital and voting rights by them.
Considering the 85.6% of the capital that will be acquired by Zydus Lifesciences Limited from PAI Partners, the management of Amplitude Surgical and two minority shareholders, Zydus Lifesciences Limited will be in a position with these undertakings to acquire more than 90% of the capital and voting rights of Amplitude Surgical at the end of the tender offer.
These undertakings to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company's capital and voting rights, may be revoked in the event of a competing tender offer ...
|
|
|
26.03.25 - 18:03
|
Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA (Business Wire)
|
|
|
Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position of €19.8 M at December 31, 2024
Revision of the Group's outlook, with sales growth in 2025 of between 6% and 7%.
VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its results for the first half of the 2024-25 financial year.
Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "The Amplitude Surgical Group's sales for the first half of the 2024-25 financial year were up +6.3% at constant exchange rates compared with the first half of the previous year. The increase in sales, combined with tight control of operating expenses, resulted in EBITDA growth of +10.6% to €13.1 million. Profit from recurring operations was €6.0 million, up on ...
|
|
|
12.03.25 - 11:51
|
XFRA : 1AU: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
AMPLITUDE SURGIC. EO -,01 1AU FR0012789667
AB/FROM ONWARDS 12.03.2025 11:47 CET...
|
|
|
11.03.25 - 23:12
|
Zydus Life in negotiations to buy French medtech firm (Times of India)
|
|
|
Zydus Lifesciences announced it is negotiating to acquire a majority stake in French medtech firm Amplitude Surgical for approximately Rs 2,500 crore. The acquisition aims to boost Zydus's global medtech ambitions, leveraging its expertise in life sciences. The deal includes a 81% premium over Amplitude Surgical's last closing price, aiming for full ownership and delisting....
|
|
|
11.03.25 - 15:42
|
XFRA : 1AU: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
AMPLITUDE SURGIC. EO -,01 1AU FR0012789667 BAW/UFN...
|
|
|
|
|
11.03.25 - 09:36
|
Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France (Business Wire)
|
|
|
Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical, France, at a price of €6.25 per Amplitude Surgical share.
Purchase consideration amounts to €256.8mn for 85.6% of the outstanding shares and voting rights of Amplitude Surgical1.
Subject to closing of the controlling block acquisition, Zydus would file a mandatory simplified cash tender offer for all the remaining shares in Amplitude Surgical, at the same purchase price of €6.25 per Amplitude Surgical share. If the conditions are met at the end of the tender offer, Zydus intends to proceed with a compulsory acquisition of the remaining shares from the minority shareholders (squeeze-out) and to delist the Company.
AHMEDABAD, India & VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Zydus Lifesciences Limited2 (“Zydus”), a global innovation-driven lifesciences company has entered into exclusive negotiations to ...
|
|
|
20.02.25 - 18:06
|
Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates (Business Wire)
|
|
|
Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with sales up +12.6% at constant exchange rates
VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for the first half of the 2024-25 financial year.
Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first half of the 2024-25 financial year, Amplitude Surgical continued its good momentum following the previous financial year, posting growth of +6.3% at constant exchange rates compared with the first half of 2023-24. This good performance was achieved thanks to growth in the activity of international subsidiaries (+12.6% at constant exchange rates) and the continuation of the good level recorded in France of +4.6%.&...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
